This clinical trial is focused on studying the treatment of peritonitis, a serious infection of the lining of the abdominal cavity. The study will explore the effectiveness of three medications: fosfomycin, metronidazole, and a substance known as recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). These medications will be administered directly into the abdominal area to see if they can improve treatment outcomes for patients undergoing surgery for this condition.
The purpose of the study is to determine if this combination of medications can optimize the treatment of patients with multiquadrant peritonitis, which means the infection affects multiple areas of the abdomen. Participants in the study will receive either the medication combination or a placebo. The study will monitor changes in certain biological markers and overall recovery to assess the effectiveness of the treatment.
Throughout the study, participants will undergo regular assessments to track their progress and any changes in their condition. The trial aims to provide valuable insights into improving treatment strategies for those affected by this challenging condition. The study is expected to continue until 2030, with recruitment starting in 2025.



Denmark